Ontology highlight
ABSTRACT: Background
As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assessed.Objective
Characterize safety and humoral immune response following the third dose of COVID-19 vaccination in a large cohort of MS patients.Methods
We assessed the safety of the third dose of the BNT162b2-COVID-19 mRNA vaccination in adult MS patients and evaluated SARS-CoV-2 IgG response.Results
Two hundred and eleven adult MS patients received a third dose of BNT162b2 COVID-19 vaccination. Median follow up time was 66 days from vaccine administratio
SUBMITTER: Dreyer-Alster S
PROVIDER: S-EPMC8779784 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature